Needham analyst Mike Matson downgraded ResMed (NYSE: RMD) from Buy to Hold.The analyst comments "We continue to expect a modest ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE